Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen’s Aduhelm

 
• By Mandy Jackson
Medicine stops disease domino effect
Biogen/Eisai's Aduhelm is first to market but other anti-amyloid drugs, like donanemab, will feel the NCD decision impact • Source: Alamy

More from Drug Pricing

More from Scrip